OPS.TO - Opsens Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.8400
-0.0100 (-1.18%)
At close: 2:25PM EST
Stock chart is not supported by your current browser
Previous Close0.8500
Open0.8500
Bid0.8400 x 0
Ask0.8700 x 0
Day's Range0.8300 - 0.8500
52 Week Range0.7300 - 1.0500
Volume15,806
Avg. Volume35,423
Market Cap75.835M
Beta (5Y Monthly)1.20
PE Ratio (TTM)N/A
EPS (TTM)-0.0550
Earnings DateJan 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.87
  • CNW Group

    Opsens - Election Results for the Board of Directors

    Opsens - Election Results for the Board of Directors

  • CNW Group

    Opsens Receives FDA Approval of Optowire III

    QUEBEC CITY , Jan. 13, 2020 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (OPS.TO) (OPSSF) today announced 510(k) clearance from the U.S. Food and Drug Administration ("FDA") to market its OptoWire III, a coronary pressure guidewire for physiological measurements such as Fractional Flow Reserve ("FFR") and Diastolic Pressure Ratio ("dPR"). The OptoWire family of products are used to diagnose and guide the treatment of patients with coronary heart disease. "Opsens is pleased to receive this important regulatory approval as we continue to optimize both the performance and production of our flagship product family." said Louis Laflamme , President and Chief Executive Officer of the Company.

  • CNW Group

    Opsens - Announces Q1 2020 Results

    Opsens - Announces Q1 2020 Results

  • Is Opsens (TSE:OPS) A Risky Investment?
    Simply Wall St.

    Is Opsens (TSE:OPS) A Risky Investment?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

  • CNW Group

    Opsens Receives dPR Clearance from the FDA

    QUEBEC CITY , Dec. 19, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (OPS.TO) (OTCQX: OPSSF) announces 510(k) clearance from the U.S. Food and Drug Administration ("FDA") to market its diastolic pressure algorithm ("dPR"). Coronary physiology has been in constant evolution with the expanded use of Fractional Flow Reserve ("FFR") and the support of strong clinical data and cardiology societies recommendations. Opsens has developed its proprietary diastolic pressure ratio (dPR) to meet this need.

  • Opsens Inc. (TSE:OPS): Is Breakeven Near?
    Simply Wall St.

    Opsens Inc. (TSE:OPS): Is Breakeven Near?

    Opsens Inc.'s (TSE:OPS): Opsens Inc. develops, manufactures, installs, and sells fiber optic sensors for interventional...

  • CNW Group

    Opsens - Record FY2019 Consolidated Revenues of $32.8 M, Up 36%, Record FFR Revenues of $20M, Up 41%

    Opsens - Record FY2019 Consolidated Revenues of $32.8 M, Up 36%, Record FFR Revenues of $20M, Up 41%

  • Opsens - First clinical use of OptoWire III after Health Canada approval
    CNW Group

    Opsens - First clinical use of OptoWire III after Health Canada approval

    QUEBEC CITY , Nov. 7, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (OPS.TO) (OTCQX:OPSSF) today announced the world's first clinical use of the OptoWire III, following the recent Health Canada approval. OptoWire III is a coronary guidewire integrating a second-generation optical sensor for vascular physiological measurement, such as Fractional Flow Reserve ("FFR"). This pressure guidewire is designed to offer the lowest drift in the industry and excellent access to lesions.

  • CNW Group

    Opsens Announces Entry Into Structural Heart Market

    QUEBEC CITY , Nov. 5, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (OPS.TO) (OTCQX: OPSSF) announces today it is expanding its medical device business into the structural cardiology space and will accelerate development activities of products that reach beyond its current coronary and peripheral applications. Louis Laflamme , President and Chief Executive Officer commented, "Opsens' technical and commercial capabilities have expanded over the last few years, fueled by our success in the coronary market. The initial area of focus is aortic stenosis, a common and serious valve disease that is often treated through Trans Aortic Valve Replacement (TAVR).

  • How Does Investing In Opsens Inc. (TSE:OPS) Impact The Volatility Of Your Portfolio?
    Simply Wall St.

    How Does Investing In Opsens Inc. (TSE:OPS) Impact The Volatility Of Your Portfolio?

    If you own shares in Opsens Inc. (TSE:OPS) then it's worth thinking about how it contributes to the volatility of your...

  • Do Insiders Own Shares In Opsens Inc. (TSE:OPS)?
    Simply Wall St.

    Do Insiders Own Shares In Opsens Inc. (TSE:OPS)?

    Every investor in Opsens Inc. (TSE:OPS) should be aware of the most powerful shareholder groups. Large companies...

  • Why Opsens Inc.'s (TSE:OPS) CEO Pay Matters To You
    Simply Wall St.

    Why Opsens Inc.'s (TSE:OPS) CEO Pay Matters To You

    In 2013 Louis Laflamme was appointed CEO of Opsens Inc. (TSE:OPS). This report will, first, examine the CEO...

  • CNW Group

    Opsens Solutions - Strategic Order for Fiber Optic Sensors to be Deployed in New Industrial Dewatering Process

    QUEBEC CITY , July 16, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (OPS.TO) (OTCQX: OPSSF) today announced that Opsens Solutions Inc. ("Opsens Solutions"), its wholly-owned subsidiary, has received an order for more than a hundred fiber optic sensors and systems, to be deployed in a new dewatering process of oil sands tailings. The order was placed by ElectroKinetic Solutions, a company that has developed an innovative process which allows large volumes of tailing deposits to be dewatered rapidly with substantially lower energy requirements than conventional processes.  Opsens Solutions will provide fiber optic monitoring systems and sensors that will optimize the dewatering operations to prevent negative impacts on the environment. "Our fiber optic technology can be adapted to measure various parameters in the most difficult conditions to deliver significant benefits in terms of process optimization and risk reduction to the environment and health, which are compelling sales arguments for many industries," said Gaétan Duplain, President of Opsens Solutions.

  • CNW Group

    Opsens - Q3 2019 - Record Quarterly FFR Revenues of $5.2 M, Up 49%

    Opsens - Q3 2019 - Record Quarterly FFR Revenues of $5.2 M, Up 49%

  • Why Opsens Inc. (TSE:OPS) Is An Attractive Investment To Consider
    Simply Wall St.

    Why Opsens Inc. (TSE:OPS) Is An Attractive Investment To Consider

    Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on...

  • These Fundamentals Make Opsens Inc. (TSE:OPS) Truly Worth Looking At
    Simply Wall St.

    These Fundamentals Make Opsens Inc. (TSE:OPS) Truly Worth Looking At

    I've been keeping an eye on Opsens Inc. (TSE:OPS) because I'm attracted to its fundamentals. Looking at the company as...

  • GlobeNewswire

    UPDATE - Opsens Solutions Partners With Temai Ingenieros for the Commissioning of an Optical-Based Fuel Monitoring System for a Major Aircraft Manufacturer

    Opsens Inc. ("Opsens" or the "Company") (OPS.TO) (OTCQX:OPSSF) today announced that Opsens Solutions Inc. ("Opsens Solutions"), its wholly-owned subsidiary, is partnering with Temai Ingenieros S.L. ("Temai") for the commissioning of an optical-based fuel monitoring system for a major aircraft manufacturer. This agreement comes after over a year of development and ground testing of an aircraft fuel monitoring system based on Opsens Solutions’ fiber optic sensing technology.

  • CNW Group

    Opsens Solutions Further Expands Intellectual Property Portfolio with USPTO Grant

    QUEBEC CITY , June 11, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (OPS.TO) (OPSSF) today announced that its wholly-owned subsidiary Opsens Solutions Inc. ("Opsens Solutions"), has been granted a patent for an innovative optical-based pressure sensor from the United States Patent and Trademark Office ("USPTO"). Patent no. 10,082,437 entitled "Optical Pressure Sensor with Reduced Mechanical Stresses" describes an innovative fiber optic pressure sensor design aimed at solving sensor drift, one of the most challenging problems encountered with sensors used in high pressure environments. Tested by a world-renowned, independent laboratory, this new fiber optic pressure sensor has shown unparalleled low-drift performances when measuring minute changes in differential pressure.

  • ACCESSWIRE

    Opsens To Present at the LD Micro Invitational

    QUEBEC CITY, QC / ACCESSWIRE / May 22, 2019 / Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) ( OTCQX: OPSSF ) , a company focusing mainly on physiological measurements such as Fractional ...

  • Some Opsens (TSE:OPS) Shareholders Are Down 35%
    Simply Wall St.

    Some Opsens (TSE:OPS) Shareholders Are Down 35%

    For many investors, the main point of stock picking is to generate higher returns than the overall market. But in any...

  • Opsens Signs Landmark Supplier Agreement - Expands Optical Sensing Technology Impact Within Cardiology Segment
    CNW Group

    Opsens Signs Landmark Supplier Agreement - Expands Optical Sensing Technology Impact Within Cardiology Segment

    QUEBEC CITY , April 30, 2019 /CNW Telbec/ - Opsens inc. ("Opsens" or the "Company") (OPS.TO) (OPSSF) is pleased to announce it has entered into a supply agreement as part of its long-term collaboration with Abiomed, Inc. ("Abiomed") for the Impella CP® heart pump. Abiomed has awarded Opsens a five-year agreement to supply a critical component for its heart pump technology. This new agreement between Opsens and Abiomed follows a co-development and license agreement to integrate Opsens' miniature optical pressure sensor into Impella CP® heart pumps, signed in 2014.

  • Does Opsens Inc. (TSE:OPS) Have A Volatile Share Price?
    Simply Wall St.

    Does Opsens Inc. (TSE:OPS) Have A Volatile Share Price?

    If you own shares in Opsens Inc. (TSE:OPS) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Volatility is considered to be a measure of ris...

  • CNW Group

    Opsens - Q2 2019 Revenues Reach $7.9 M, a 46% Increase

    Opsens - Q2 2019 Revenues Reach $7.9 M, a 46% Increase

  • Opsens Appoints Alan Milinazzo as Executive Chairman of the Board of Directors
    CNW Group

    Opsens Appoints Alan Milinazzo as Executive Chairman of the Board of Directors

    QUEBEC CITY , March 4, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens") (OPS.TO) (OPSSF) is pleased to announce the appointment of Mr. Alan Milinazzo as Executive Chairman of the Board of Directors. "We are delighted to see Alan, a renowned leader in the medical device industry, join us. Alan has had extensive success in building high-performance commercial teams in interventional cardiology.

  • CNW Group

    Opsens announces credit agreement with CIBC Innovation Banking

    QUEBEC CITY , Feb. 27, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens") (OPS.TO) (OPSSF) is pleased to announce that it has entered into an $8 M credit agreement (the "Agreement") with CIBC Innovation Banking (CIBC). "The Agreement offered carries excellent conditions. The Agreement consists of a $7 M term loan, set to mature in 60 months and of a $1 M revolving operating credit margin, set to mature in one year and that may be renewed on an annual basis.